The antibody was purified by affinity chromatography and conjugated with APC under optimal conditions. The solution is free of unconjugated APC and unconjugated antibody.
anticorps KIR3DL1, anticorps KIR3DL3, anticorps CD158E1, anticorps KIR, anticorps KIR3DL1/S1, anticorps NKAT3, anticorps NKB1, anticorps NKB1B, anticorps Kirl1, anticorps Kirl2, anticorps Krl1, anticorps killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 1, anticorps uncharacterized LOC100437736, anticorps killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1, anticorps KIR3DL1, anticorps LOC100437736, anticorps Kir3dl1
Sujet
CD158e1, also known as NKB1, is a 70 kD member of the immunoglobulin superfamily that is expressed on a subset of natural killer cells and T cells at varying levels among individuals. NKB1 is a type I membrane protein containing two immunoglobulin C2-type domains. The interaction of NKB1 with specific HLA-B antigens on a target cell (the HLA-Bw4 allele, for example) inhibits cytotoxicity and prevents target cell lysis and death. The interactions between KIR and MHC class I are thought to be important in NK and T cell regulation following antigen stimulation. The absence of ligands for KIRs may lower the threshold for activation through activating receptors and increase inflammation and susceptibility to autoimmune disease.